{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T22:00:30Z","timestamp":1776722430406,"version":"3.51.2"},"reference-count":16,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T00:00:00Z","timestamp":1773878400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>This paper reports a case of Grade IV thrombocytopenia in a 65-year-old male patient with advanced lung cancer after 4 days of concurrent treatment with selpercatinib and voriconazole. The clinical pharmacist attributed the thrombocytopenia to voriconazole exacerbating the hematological toxicity of selpercatinib and thus stopped selpercatinib and voriconazole treatment sequentially; the patient was given recombinant human thrombopoietin to raise platelets. When the platelet count returned to normal and voriconazole was discontinued, selpercatinib was restarted at a reduced dose and gradually titrated back to the original therapeutic dose. Subsequent treatment did not have any further adverse reactions. This case suggests that doctors and clinician pharmacists should be aware of the potential interaction between selpercatinib and voriconazole, avoid the use of CYP3A4 inhibitors during selpercatinib treatment, and pay attention to dose adjustment.<\/jats:p>","DOI":"10.3389\/fonc.2026.1680060","type":"journal-article","created":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T06:51:36Z","timestamp":1773903096000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Mechanistic insights into voriconazole-exacerbated selpercatinib-induced thrombocytopenia: a pharmacokinetic interaction case report"],"prefix":"10.3389","volume":"16","author":[{"given":"Haochun","family":"Tang","sequence":"first","affiliation":[{"name":"Department of Pharmacy, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital and Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Shenzhen, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ziyuan","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital and Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Shenzhen, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuelin","family":"Zhang","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Guangdong Medical University","place":["Dongguan, Guangdong, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenjun","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital and Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Shenzhen, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Meng","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital and Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Shenzhen, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guohui","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital and Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Shenzhen, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-022-00935-5","article-title":"Selpercatinib: A review in advanced RET fusion-positive NSCLC","volume":"18","author":"Nie","year":"2023","journal-title":"Target Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01343-7","article-title":"Selpercatinib: first approval","volume":"80","author":"Markham","year":"2020","journal-title":"Drugs"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2309457","article-title":"First-line selpercatinib or chemotherapy and pembrolizumab in RET fusion-positive NSCLC[J","volume":"389","author":"Caicun","year":"2023","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00541-1","article-title":"Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1\/2, open-label, basket trial","volume":"23","author":"Subbiah","year":"2022","journal-title":"Lancet Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00393","article-title":"Selpercatinib in patients with RET fusion-positive non-small-cell lung cancer: updated safety and efficacy from the registrational LIBRETTO-001 phase I\/II trial","volume":"41","author":"Drilon","year":"2023","journal-title":"J Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3390\/ph14111087","article-title":"P-glycoprotein (ABCB1\/MDR1) and BCRP (ABCG2) limit brain accumulation and cytochrome P450-3A (CYP3A) restricts oral exposure of the RET inhibitor selpercatinib (RETEVMO)","volume":"14","author":"Wang","year":"2021","journal-title":"Pharmaceuticals"},{"key":"B7","doi-asserted-by":"publisher","first-page":"100213","DOI":"10.1016\/j.dmd.2025.100213","article-title":"P-gp\/BCRP efflux and intestinal metabolism limit tigecycline exposure: Effects of elacridar and voriconazole in mice","volume":"54","author":"Zi\u00f3\u0142kowski","year":"2026","journal-title":"Drug Metab Disposition"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01123-08","article-title":"Comprehensive in vitro analysis of voriconazole inhibition of eight cytochrome P450 (CYP) enzymes: major effect on CYPs 2B6, 2C9, 2C19, and 3A","volume":"53","author":"Jeong","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.31.5.540","article-title":"Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole","volume":"31","author":"Hyland","year":"2003","journal-title":"Drug Metab Disposition"},{"key":"B10","unstructured":"Lilly\n              E\n            \n          \n          RETEVMOTM (selpercatinib): US prescribing information\n          \n          2020"},{"key":"B11","doi-asserted-by":"publisher","first-page":"e18636","DOI":"10.7717\/peerj.18636","article-title":"CYP3A4 and CYP3A5: the crucial roles in clinical drug metabolism and the significant implications of genetic polymorphisms","volume":"12","author":"Zhang","year":"2024","journal-title":"PeerJ"},{"key":"B12","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1007\/s40262-019-00856-z","article-title":"A physiologically based pharmacokinetic model of voriconazole integrating time-dependent inhibition of CYP3A4, genetic polymorphisms of CYP2C19 and predictions of drug-drug interactions","volume":"59","author":"Li","year":"2020","journal-title":"Clin Pharmacokinet"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.22037\/IJPR.2015.1770","article-title":"Sunitinib induced immune thrombocytopenia","volume":"14","author":"Shekarriza","year":"2015","journal-title":"Iran J Pharm Res"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020006302","article-title":"Activation of the receptor tyrosine kinase RET improves long-term hematopoietic stem cell outgrowth and potency - ScienceDirect","volume":"136","author":"Grey","year":"2020","journal-title":"Blood"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.14053\/j.cnki.ppcr.202112021","article-title":"A new drug in treating non-small cell lung cancer: RET gene fusion-positive inhibitor-pralsetinib","volume":"24","author":"Huang","year":"2021","journal-title":"Pract Pharm Clin Remedies"},{"key":"B16","doi-asserted-by":"publisher","first-page":"e70064","DOI":"10.1002\/prp2.70064","article-title":"Phase I study of the safety, tolerability, and pharmacokinetics of inhaled voriconazole in healthy volunteers and subjects with stable asthma","volume":"13","author":"Caponetti","year":"2025","journal-title":"Pharmacol Res Perspect"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1680060\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T06:51:37Z","timestamp":1773903097000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1680060\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,19]]},"references-count":16,"alternative-id":["10.3389\/fonc.2026.1680060"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1680060","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,19]]},"article-number":"1680060"}}